Discover how Capricor Therapeutics’ CAP-1002 targets DMD cardiomyopathy. Learn about upcoming data, approval prospects, and ...
Get insights on the upcoming HOPE 3 phase 3 trial, key endpoints, and investment risks for CAPR. Learn what to watch in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback